Brief: Mereo BioPharma Reports Clinical Update From Activate Phase 1B/2 Open Label Study Of Etigilimab Plus Nivolumab
12/09/2022 14:34
Sept 12 (Reuters) - Mereo Biopharma Group PLC MAH0y.F :
* MEREO BIOPHARMA REPORTS CLINICAL UPDATE AND INTERIM
BIOMARKER
ANALYSIS PRESENTED AT ESMO 2022 FROM ACTIVATE PHASE 1B/2 OPEN
LABEL STUDY OF ETIGILIMAB (ANTI-TIGIT ANTIBODY MPH-313) PLUS
NIVOLUMAB (ANTI-PD-1 ANTIBODY) IN SOLID TUMORS
* MEREO BIOPHARMA - DATA SUPPORT FURTHER EVALUATION OF PVR,
CD226,
AND TIGIT AS POTENTIAL BIOMARKERS OF ENRICHMENT FOR ETIGILIMAB
PLUS ANTI-PD1 THERAPY
* MEREO BIOPHARMA - CONTINUED CLINICAL BENEFIT OBSERVED WITH
COMBINATION OF ETIGILIMAB AND NIVOLUMAB, INCLUDING IN PD-L1
NEGATIVE OR LOW SUBJECTS
Source text for Eikon: ID:nGNX3kxptC
Further company coverage: MAH0y.F
((Reuters.Briefs@thomsonreuters.com;))
Recent news on Mereo BioPharma
See all newsBrief: Sentynl Therapeutics And Mereo Biopharma Announce Option And License Agreement For Alvelestat In Alpha-1 Antitrypsin Deficiency-Associated Lung Disease
UK's Mereo BioPharma Q2 loss narrows on lower R&D spending
Brief: Mereo BioPharma Q2 Operating Income USD -7.03 Million
Brief: Mereo BioPharma Q1 Net Income USD -6.719 Million
Brief: Mereo BioPharma FY Revenue USD 500 Thousand Vs. IBES Estimate USD 520 Thousand